Tag: ESMO

Latest News

NOXXON PRÄSENTIERT AKTUELLE KLINISCHE DATEN AUS DER NOX-A12 / KEYTRUDA®- PHASE-1/2-KOMBINATIONSSTUDIE AUF DEM ESMO KONGRESS

Newsemia
BERLIN–(BUSINESS WIRE)–NOXXON Pharma N.V. (Paris:ALNOX) (Euronext Growth Paris: ALNOX), ein Biotechnologieunternehmen mit Fokus auf der Verbesserung von Krebstherapien durch eine gezielte Einwirkung auf die Tumormikroumgebung...
Latest News

ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO

Newsemia
WALTHAM, Mass.–(BUSINESS WIRE)–IMGN Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO Source link...
Latest News

Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

Newsemia
BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO)...
Latest News

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at European Society for Medical Oncology (ESMO) Congress

Newsemia
BARCELONA, Spain–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial...
Latest News

ESMO 2019: Forbius Demonstrates Target Engagement in Phase 1 Immuno-Oncology Clinical Trial with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor

Newsemia
AUSTIN, Texas & MONTREAL–(BUSINESS WIRE)– #Austin–Forbius, a clinical-stage protein engineering company that develops biotherapeutics to treat fibrosis and cancer, today reported results from its non-clinical...
Latest News

ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress

Newsemia
WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced initial safety...
Latest News

Genentech to Present New Positive Data from Its Broad Cancer Immunotherapy Program and across a Wide Range of Cancers at the European Society for Medical Oncology (ESMO) 2018 Congress

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new results from a number of...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World